G209 - 2M, gp100 (209 - 217)

Description:

This modified gp100 peptide is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. It holds promise for the development of novel cancer immunotherapies.

Sequence:

IMDQVPFSV

General

References

Comments (0)

Name	G209 - 2M, gp100 (209 - 217)
Category	Cancer Research Peptides
One Letter Code	IMDQVPFSV
Three Letter Code	{Ile}{Met}{Asp}{Gln}{Val}{Pro}{Phe}{Ser}{Val}
Molecular Weight	1035.200
Application	Antigen-presenting CellsCancer Research

Schaed, Susanne G., et al. "T-cell responses against tyrosinase 368–376 (370D) peptide in HLA∗ A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants." Clinical cancer research 8.5 (2002): 967-972.

Paczesny, Sophie, et al. "Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells." The Journal of experimental medicine 199.11 (2004): 1503-1511.

Dudley, Mark E., et al. "T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes." Cancer journal (Sudbury, Mass.) 6.2 (2000): 69-77.

Fritsch, Michael, Steven A. Rosenberg, and Paul H. Duray. "Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine." Journal of Immunotherapy 23.5 (2000): 557-569.